Geron Corporation (GERN) Phase 3 Data Favors Imetelstat Versus Real World Data - HC Wainwright

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating and $7.00 price target on Geron Corporation (NASDAQ: GERN) after the company announced positive data from the IMbark Phase 2 study of 9.4 mg/kg imetelstat (n=57) compared to best available therapy (BAT) in patients with intermediate-2 or high-risk myelofibrosis (MF) refractory to JAK-Inhibitor treatment (refractory MF) (n=38).

The analyst stated "Notably, imetelstat-treated patients had a median OS of approximately 30 months, which was 2.5 times higher than the approximately 12 months OS observed in real world data in BATtreated patients. We see this comparison as promising for Geron’s ongoing IMpactMF Phase 3 trial, and expect similar results from interim analysis we look for in 2024 and in a final data analysis in 2025. We believe imetelstat, whose telomerase inhibitory activity selectively
targets malignant cells, could be a highly differentiated new treatment for MF."

For an analyst ratings summary and ratings history on Geron Corporation click here. For more ratings news on Geron Corporation click here.

Shares of Geron Corporation closed at $1.38 yesterday.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
• NMG launches Matawinie mine construction after C$427M equity raise
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform